You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Temozolomide Perillyl Alcohol Conjugate as Treatment for Recurrent Malignant Brain tumors

    SBC: NEONC TECHNOLOGIES INC            Topic: BT

    DESCRIPTION provided by applicant Glioblastoma multiforme GBM the most common and malignant of all gliomas has a median survival time of months Standard of care chemotherapy using temozolomide TMZ is effective initially but the GBM inevitably recurs and these recurrent tumors are resistant to TMZ There are currently no effective treatment options for patients with TMZ resistant ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Ultrasensitive Point-of-Care Diagnostics of Viral Biomarkers and Infectious Diseases

    SBC: ARISAN THERAPEUTICS INC            Topic: NIAID

    Project Summary Linking infectious agent diagnostics to clinical decision making at the point of care requires a fast highly sensitive and simple to use method that takes into account the infrastructure and workflow in clinical settings of both developing and developed regions In addition being able to distinguish among multiple potential infectious pathogens in a single test is of great impor ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Simple, low cost assay for detection of HIV-1 antiretroviral resistance in resource-limited settings

    SBC: Discidium Biosciences, LLC            Topic: NIAID

    Antiretroviral therapy has become a reality in resource limited settings thanks to entities such as PEFAR and the Global Fund However contrary to the therapeutic choice flexibility in developed countries all patients go on reverse transcriptase inhibitor RTI based first line regimens with more expensive protease and integrase inhibitor based regimens being reserved as second line therapy for ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Therapeutic inhibition of P. aeruginosa nitrogen respiration in chronic infection

    SBC: L2 DIAGNOSTICS LLC            Topic: NIAID

    DESCRIPTION provided by applicant The goal of this STTR is to identify novel small molecule compounds targeting the nitrogen respiration pathway of Pseudomonas aeruginosa This pathway is crucial to the pathogenesis of P aeruginosa in vivo but has not yet been exploited for antimicrobial drug discovery There is a clear need for new treatments to combat P aeruginosa infections Antibiotic re ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. Oncolytic virus-mediated target delivery of a therapeutic antibody fragment in glioblastoma

    SBC: Oncosynergy, Inc.            Topic: 102

    PROJECT SUMMARY More thanpatients are diagnosed each year with glioblastomathe most common primary brain tumorCurrent treatments are inadequate and there have been no major therapeutic breakthroughs in decadesHencethere is an urgent need to develop novel strategies to address this devastating diseaseHoweverdevelopment of an effective treatment for glioblastoma is severely hampered bythe blood brai ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
  6. C/EBP-beta PEPTIDES FOR THE TREATMENT OF LIVER INJURY AND FIBROSIS

    SBC: XFIBRA, INC.            Topic: NIDDK

    DESCRIPTION (provided by applicant): Activation of hepatic stellate cells (HSC) is responsible for the development of liver fibrosis in chronic liver diseases of all causes and remarkably, HSC clearance by apoptosis may allow recovery from liver injury andreversal of liver fibrosis. There is full agreement among liver fibrosis experts that inhibiting o reversing HS activation (the therapeutic targ ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Development of a novel platform to enhance intracellular bioavailability of antisense morpholino oligomers

    SBC: NAJIT TECHNOLOGIES, INC.            Topic: NIAID

    DESCRIPTION provided by applicant Peptide conjugated phosphorodiamidate morpholino oligomers PPMO are single stranded nucleic acid analogs able to modulate gene expression through steric blocking of complementary RNA PPMO are composed of two components an antisense morpholino oligomer cargo covalently conjugated to a cell penetrating delivery peptide PPMO are completely nuclease resistant ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  8. In vivo expansion of human hepatocytes in Fah-/-Rag-/-Il2rg-/- mice

    SBC: Yecuris Corporation            Topic: NCRR

    DESCRIPTION (provided by applicant): The liver is the site of many metabolic processes, including metabolism of xenobiotics such as pharmaceutical compounds. Drug metabolism is highly species specific and can vary significantly between individuals of the same species. To date no reliable experimental system capable of predicting the human-specific metabolic conversion of candidate small molecules ...

    STTR Phase I 2010 Department of Health and Human ServicesNational Institutes of Health
  9. Pulse Oximeter for Newborn Screening

    SBC: INTELLIGENT OPTICAL SYSTEMS, INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): Congenital heart diseases (CHD) are the most common serious congenital anomalies and the leading cause of death due to birth defects. Clinical practice relying on physical examination of the newborn before discharge from the nursery often misses newborns with critical CHD (CCHD), which can lead to death or long-term morbidities. Using pulse oximetry (PO) can im ...

    STTR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  10. High-Throughput Assay for Profiling Alternative Splicing and Splicing Regulators

    SBC: Biospyder Technologies, Inc.            Topic: 172

    SummaryThis Phase I program will develop TempO Splicea highly multiplexed targeted sequencing assay monitoring RNA Binding ProteinRBPsplicing expression and alternatively splicedASmRNA representatives of coregulated splicing modulesa novel variation of the TempO Seqassay used for high throughput screeningdesigned to address the hypothesis that it is possible to provide a surrogate assay of the who ...

    STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government